A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus
Phase 2
- Conditions
- ObesityType2 Diabetes
- Interventions
- Drug: PlaceboDrug: CT-868
- Registration Number
- NCT05110846
- Lead Sponsor
- Carmot Therapeutics, Inc.
- Brief Summary
A Study to Assess the effect of CT-868 in hemoglobin A1c (HbA1c) in Overweight and Obese Participants with Type 2 Diabetes Mellitus.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 96
Inclusion Criteria
- Males or Females with T2DM
- BMI of ≥27 kg/m2, inclusive
- 18-75 years old, inclusive
- Stable body weight for 3 months
Read More
Exclusion Criteria
- Significant medical history
- Uncontrolled diabetes
- History of malignancy
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo Placebo CT-868 Low Dose CT-868 CT-868 CT-868 Maximum Tolerated Dose CT-868 CT-868
- Primary Outcome Measures
Name Time Method Change in hemoglobin A1c (HbA1c) Baseline up to 12 and 26 weeks
- Secondary Outcome Measures
Name Time Method Change in mean body weight Baseline up to 12 and 26 weeks Fasting plasma glucose Baseline up to 12 and 26 weeks
Trial Locations
- Locations (6)
Carmot Clinical Center MX05
🇲🇽Mérida, Yucatan, Mexico
Carmot Clinical Center MX03
🇲🇽Mexico City, Mexico
Carmot Clinical Center MX04
🇲🇽Guadalajara, Jalisco, Mexico
Carmot Clinical Center MX01
🇲🇽Monterrey, Nuevo Leon, Mexico
Carmot Clinical Center US01
🇺🇸Los Angeles, California, United States
Carmot Clinical Center MX02
🇲🇽Monterrey, Nuevo Leon, Mexico